miR-101 was shown to specifically target EZH2 for down regulation in prostate cancer cells, and the miR-101 locus was deleted in 37.5% of localized prostate cancers and 66.7% of castrate-resistant metastatic prostate cancer cases. This evidence concerns the gene EZH2 and prostate cancer.